About Bluebird Bio
Bluebird Bio is a company based in Cambridge (United States) founded in 1992 was acquired by The Carlyle Group in February 2025. Bluebird Bio has raised $210.68 million across 11 funding rounds from investors including ABN AMRO, The Carlyle Group and RA Capital. Bluebird Bio has completed 1 acquisition, including Pregenen. Bluebird Bio offers products and services including Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy. Bluebird Bio operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bluebird Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$210.68 M (USD)
in 11 rounds
-
Latest Funding Round
Not available
-
Investors
ABN AMRO
& 11 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
The Carlyle Group
(Feb 21, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bluebird Bio
Bluebird Bio offers a comprehensive portfolio of products and services, including Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy.
FDA-approved one-time therapy to treat sickle cell disease genetically.
Treatment using lentiviral vectors for beta-thalassemia genetic disorder.
Gene-based approach to address cerebral adrenoleukodystrophy symptoms.
People of Bluebird Bio
Unlock access to complete
Unlock access to complete
Leadership Team
42 people
Software Development Team
26 people
Senior Team
12 people
Sales and Marketing
6 people
Operations Team
5 people
Data Analysis and Operations Team
3 people
Product Management Team
3 people
QC Team
2 people
Unlock access to complete
Funding Insights of Bluebird Bio
Bluebird Bio has successfully raised a total of $210.68M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bluebird Bio
Bluebird Bio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ABN AMRO, The Carlyle Group and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for Bluebird Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bluebird Bio
Bluebird Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pregenen.
Investment portfolio details for Bluebird Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Limited information available
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Bluebird Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Bluebird Bio
Detailed financials for Bluebird Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bluebird Bio Comparisons
Peer comparison for Bluebird Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bluebird Bio
Bluebird Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Bluebird Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bluebird Bio
Complete news archive for Bluebird Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bluebird Bio
Bluebird Bio was founded in 1992 and raised its 1st funding round 12 years after it was founded.
Bluebird Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Bluebird Bio is a funded company, having raised a total of $210.68M across 11 funding rounds to date.
Bluebird Bio was founded in 1992 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed by the company for severe genetic diseases and rare conditions, including Lenti-D for childhood cerebral adrenoleukodystrophy and LentiGlobin for rare hemoglobinopathies. Preclinical programs are pursued for multiple myeloma and HPV-associated cancers. Homing endonuclease and megaTAL gene-editing technologies are applied in hematology and oncology areas.
Bluebird Bio's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Bluebird Bio offers Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy.
Bluebird Bio has made 1 acquisition, including Pregenen.
Bluebird Bio has 12 investors. Key investors include ABN AMRO, The Carlyle Group, RA Capital, Arch Venture Partners, and Tang Capital Partners.